Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients-Reference-Cited by-同舟云学术

Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients

Published:2006-05-03 Issue:3 Volume:98 Page:241-248
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Tampellini Marco,Berruti Alfredo,Bitossi Raffaella,Gorzegno Gabriella,Alabiso Irene,Bottini Alberto,Farris Antonio,Donadio Michela,Sarobba Maria Giuseppa,Manzin Enrica,Durando Antonio,Defabiani Enza,De Matteis Andrea,Ardine Mara,Castiglione Federico,Danese Saverio,Bertone Elena,Alabiso Oscar,Massobrio Marco,Dogliotti Luigi

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-005-9155-y.pdf

Reference32 articles.

1. De Angelis R, Capocaccia R, Verdecchia A. 1997 Estimating relative survival of Italian cancer patients from sparse cancer registries data.Tumori83:33–38

2. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O’Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ. 2000 Prognostic factors in breast cancer. College of American Pathologist Consensus Statement 1999 Arch Pathol Lab Med 124:966–978

3. Isaacs C, Stearns V, Hayes DF. 2001 New prognostic factors for breast cancer recurrenceSemin Oncol 28:53–67

4. Clark GM, Sledge GW, Kent Osborne C, McGuire WL. 1987 Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patientsJ Clin Oncol 5:55–61

5. Miller AB, Hogestraeten B, Staquet M, Winkler A. 1981 Reporting results of cancer treatmentCancer 47:207–214

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor marker-based RecistTM is superior to RECIST as criteria to predict the long-term benefits of targeted therapy in advanced non-small-cell lung cancer with driver gene mutations;Neoplasia;2024-07

2. Liquid biopsy utilizing miRNA in patients with advanced breast cancer treated with cyclin‑dependent kinase 4/6 inhibitors;Oncology Letters;2024-02-28

3. Association between CA 15‑3 and progression of interstitial lung disease in a case of coexisting systemic sclerosis and recurrent breast cancer: A case report;Molecular and Clinical Oncology;2022-08-08

4. CA 15-3 and molecular subtype of Invasive Ductal Carcinoma: A Systematic Review;INT J EARLY CHILD SP;2022

5. CA 15-3 and molecular subtype of Invasive Ductal Carcinoma: A Systematic Review;INT J EARLY CHILD SP;2022